A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
- Sponsor:
- ECOG-ACRIN Cancer Research Group
- Sponsor Study ID:
- EA7222
- CTO #:
- 104110
- NCT Number:
- NCT06422806
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Soft Tissue
- Study Objectives:
- To assess whether the combination of doxorubicin and pembrolizumab will improve progression free survival in UPS and related poorly differentiated sarcomas relative to doxorubicin alone.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Rangel, Christopher, at rangelc@musc.edu .
- Study Coordinator, Newman, Eva, at newmanev@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina